Page 664 - WSAVA2018
P. 664

 25-28 September, 2018 | Singapore
WSVA8-0148
CRITICAL CARE AND EMERGENCY MEDICINE
THERAPEUTIC OUTCOMES OF INJECTABLE FILGASTRIM IN EIGHT DOGS AFFECTED WITH PERSISTENT FEVER, ACUTE LEUCOPENIA AND NEUTROPENIA.
G.R. Baranidharan1, P. Narayanasami2,
J. Madurai Ganesan3, T. Bala Gangadhar3, C. Joseph4, V. Subaiah5
1Tamil Nadu Veterinary And Animal Sciences University, Madras Veterinary College- Dept Of Clinics, Chennai, India
2Tamil Nadu Veterinary and Animal Sciences University, Dept of Clinics- Madras Veterinary College, Chennai, India
3Tamil Nadu Veterinary and Animal Sciences University, Department of Veterinary Clinical Medicine - Madras Veterinary College, Chennai, India
4Tamil Nadu Veterinary and Animal Sciences University, Department of Clinics- Madras Veterinary College, Chennai, India
5Tamil Nadu Veterinary and Animal Sciences University, Department of Centralised Clinical Laboratory - Madras Veterinary College, Chennai, India
INTRODUCTION
Filgrastim is a recombinant Methionyl Human Granulocyte Colony- Stimulating Factor (r-metHuG-CSF) analog
used to stimulate the proliferation and differentiation
of granulocytes in humans undergoing chemotherapy. Recently, dogs with persistent fever (T-105° F), severe acute leucopenia and neutropenia (below 600 cells/mm) have been presented with high mortality & were taken
for study. Leucopenia from reduced production of white blood cells or increased utilization and destruction, or both are fatal. Apart from identification of the cause and effective antimicrobial therapy, recently the treatments are aimed in increasing the leucocyte counts to fight infections and related sepsis.
OBJECTIVES
To evaluate leucopenic dogs with persistent fever, post treatment with single dose subcutaneous Fligastrim injection (NEUPOGEN ®)
METHODS
Routine diagnostic tests including ultrasonography, radiography, lymph node aspirations, blood smears were done on affected dogs for confirmation. These severely leucopenic dogs were treated with Injection Filgrastim
@ 10 μg / kg b.wt subcutaneously single dose along with CRI crystalloid therapy. Clinico pathogical studies were done pre and post treatments on day 1, day 2, day3 and day 5 following Filgastrim administration
RESULTS
Seven dogs with severe leucopenia (<600 cells/cmm) responded clinically within 72 hours and their leucocyte counts increased considerably (4,200- 5800 cells/cmm). whereas one dog succumbed without clinical and clinico pathological response. No adverse reactions were encountered within 24 hours post Filgastrim injections subcutaneously.
CONCLUSIONS
Filgrastim increased the leucocyte counts within 72 hours thereby improving the survival rates in affected dogs showing early critical SIRS. Further clinical trials need to be emphasised based on these findings.
    662
43RD WORLD SMALL ANIMAL VETERINARY ASSOCIATION CONGRESS AND 9TH FASAVA CONGRESS








































































   662   663   664   665   666